β受体阻滞剂与腹膜后纤维化:是否存在关联?
结果发现132例RPF报告涉及16种单药BBA,其中12种(75%)报告呈不相称性,提示潜在安全信号,但临床证据不支持因果关系。
要点
- VigiBase中132例RPF报告涉及16种BBA,12种(75%)呈报告不相称性。
- BBA启用至RPF诊断的时间间隔无一致规律,范围0.7-264个月。
- 已发表18例中多数停药后未改善或未知,且随访数据多缺失。
核心结论
- 不相称性分析提示BBA与RPF可能存在潜在安全信号,但临床证据不支持因果关系。
主要发现
- VigiBase共报告1599例RPF个体病例安全报告,其中132例(32%)涉及16种不同的单药BBA。
- 16种BBA中有12种(75%)报告RPF呈不相称性,提示潜在安全信号。
- BBA启用至RPF诊断的时间间隔范围0.7-264个月,无一致规律。
- 多数病例(74%)停药后反应为阴性或未知。
- 已发表18例中,BBA启用至RPF诊断时间范围3-156个月,17例在诊断时停药,1例在诊断前6个月停药。
局限性
- 已发表病例随访时间短(中位数5个月),且多数(83%)缺乏相关随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Retroperitoneal fibrosis (RPF) is a rare chronic fibro-inflammatory disorder that may be secondary to certain drugs, including β-blocking agents (BBAs). However, their causative role is unclear. We aimed to investigate this association. METHODS: Disproportionality analysis was carried out on cases from 1985 to 4 October 2020 in VigiBase, the World Health Organization pharmacovigilance database. The Bayesian-based IC025 metric and reporting odds ratio were used in order to assess the adverse event signal. We also analysed all published case reports from the literature regarding BBA-associated RPF to assess the value of suggested supportive clinical evidence. RESULTS: In total, 1599 individual case safety reports of RPF were reported to VigiBase, of which 132 (32%) concerned 16 different single BBA. For 12 of these agents (75%), reporting of RPF was disproportionate, indicating a potential safety signal. Line listing analysis of individual case safety reports showed no consistent time interval from start of BBA to RPF diagnosis (range 0.7-264 mo). Dechallenge was negative or unknown in the majority of cases (74%). In 18 published cases from the literature, time from start of BBA to RPF diagnosis varied widely (range 3-156 mo). BBA were discontinued 6 months before (n = 1) or at the time of RPF diagnosis (n = 17). Most patients (84%) also received RPF specific treatment. Follow-up duration was short (median 5 mo [range 1-24 mo]) and in most cases (83%) relevant follow-up data were lacking. CONCLUSION: Although disproportionality analysis indicated a potential safety signal for RPF associated with BBAs, clinical evidence did not support a cause-and-effect relationship.
引用
- Kharagjitsing H, van Eekeren R, van Puijenbroek EP, et al. Retroperitoneal fibrosis and β-blocking agents: Is there an association? Br J Clin Pharmacol. 2021. PMID: 33326117. doi:10.1111/bcp.14702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。